Abbott IndiaBOM:500488 +0.51%87 Net Margin % is 23.10% as of Mar. 2026, which is 43% above its 10-year median of 16.15. GuruFocus rates BOM:500488 with a GF Score™ of 87/100 and a GF Value™ of ₹32,313.61 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 954 Drug Manufacturers companies, Abbott India ranks better than 90.04% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Abbott India's Net Income for the
three
months ended in Mar. 2026 was ₹3,949 Mil. Abbott India's Revenue for the
three
months ended in Mar. 2026 was ₹17,095 Mil. Therefore, Abbott India's net margin for the quarter that ended in Mar. 2026 was 23.10%.
The historical rank and industry rank for Abbott India's Net Margin % or its related term are showing as below:
BOM:500488'
s Net Margin % Range Over the Past 10 Years
Min: 9.56 Med: 16.15 Max: 22.4
Current: 22.4
BOM:500488's Net Margin % is ranked better than 90.04% of 954
companies
in the Drug Manufacturers industry
Industry Median: 5.695
vs BOM:500488: 22.40
Abbott India (BOM:500488) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Abbott India Net Margin % Related Terms
Abbott India Net Margin % Historical Data
* Premium members only.
The historical data trend for Abbott India's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Abbott India's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott India Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Abbott India's Net Margin % distribution charts can be found below:
* The bar in red indicates where Abbott India's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott India (BOM:500488) has a Net Margin % of 23.10% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Abbott India and its competitors. This is 43% above median its historical median of 16.15. Over the past decade, Abbott India's Net Margin % has ranged from 9.56 to 22.40. According to the industry distribution chart, Abbott India ranks #95 out of 954 companies in the Drug Manufacturers industry, placing it in the top 10%.
Is Abbott India's Net Margin % too high?
Abbott India's current Net Margin % of 23.10% is 43% above median its 10-year median of 16.15. Over the past 10 years, this metric has ranged from a low of 9.56 to a high of 22.40. The Drug Manufacturers industry median Net Margin % is 5.70. Abbott India's value of 23.10% is 305.6% above this industry median. Based on the distribution chart, Abbott India ranks #95 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Abbott India has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott India's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Abbott India ranks #95 out of 954 companies for Net Margin %. This places Abbott India in the top 10% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.70. Abbott India's value of 23.10% is 305.6% above this benchmark. Historically, Abbott India's own Net Margin % has ranged from 9.56 to 22.40 over the past decade. While the company's 10-year median is 16.15 vs. the industry median of 5.70, Abbott India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.70, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott India's current Net Margin % of 23.10% is 305.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Abbott India and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott India's current Net Margin % is 23.10%, which is 43% above median its own 10-year median of 16.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott India stock overvalued right now?
Based on GuruFocus' analysis, Abbott India (BOM:500488) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹32,313.61, compared to a current price of ₹25,566.95 — trading 20.9% below its estimated fair value. The current Net Margin % is 23.10%, which is 43% above median its 10-year median of 16.15 and 305.6% above the Drug Manufacturers industry median of 5.70. Abbott India's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Abbott India (BOM:500488), the current Net Margin % is 23.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott India (BOM:500488) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott India stock appears to be undervalued.
The current stock price of ₹25,566.95 is trading 20.9% below its estimated GF Value™ of ₹32,313.61.
GuruFocus considers Abbott India to be Modestly Undervalued.
Key valuation signals for BOM:500488:
Net Margin %: 23.10% (43% above median its 10-year median of 16.15)
GF Value™: ₹32,313.61 vs. price of ₹25,566.95 (20.9% below fair value)
Industry Position: 305.6% above the Drug Manufacturers median (#95 of 954)
No single metric tells the full story. See the BOM:500488 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott India Ltd is a drug manufacturing company that offers products in diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals. Its patient focus centers overwhelmingly on women's health and gastrointestine, gastroenterology, and hepatic care. Geographically, the majority of the company's revenue is generated in India.
87GF Score
Get the complete analysis for BOM:500488
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500488 has been successfully added to your 
